论文部分内容阅读
甲氟哌酸(pefloxacin,PFLO)属于氟喹诺酮类广谱抗菌剂,近年来在鼠足垫模型中证实对麻风菌有杀菌作用。为了评价其对麻风患者的疗效和可能的副作用,作者于1985年7月～1986年4月在象牙海岸的Adzope 地区对10例以往未治疗过的麻风(LL7例、BL3例)进行了PFLO 的临床试验。其中男7例,女3例;年龄24～39(31.9±3.5)岁。疗前均有活动性皮损,细菌指数(BI)和形态指数(MI)均较高。所有患者均住院治疗,给予PFLO400mg,每日2次监服,疗期6个月,疗前按WHO 麻风化疗组的方案要求检查患者,治疗开始后,每月进行临床评价及血、尿常规和肝功能试验。此外疗前及治疗2、4和6个月时作组织病理检查和小鼠足垫接种,以检测其活菌比例和疗前麻风菌对DDS 及利福平(RFP)的敏感性。结果:10株麻风菌中有4株显示低度原发性DDS 耐药,但所有菌株对RFP 均敏感。所有患者对PFLO 治疗的疗效良好,在治疗2个月时,即有肯定的临床进步,表现为浸润消退,结节变平,鼻塞好转。细菌检直疗前平均MI 为37.9%,在治疗
Pefloxacin (PFLO) is a fluoroquinolone broad-spectrum antibacterial agent. In recent years, baclofenac has been shown to be bactericidal in mouse footpad model. In order to evaluate their efficacy and possible side effects on patients with leprosy, 10 PFL patients (LL7, BL3) who were previously untreated leprosy were treated in the Adzope area of the Ivory Coast from July 1985 to April 1986 Clinical Trials. There were 7 males and 3 females, ranging in age from 24 to 39 (31.9 ± 3.5) years. Active lesions were seen before treatment, with higher bacterial index (BI) and morphological index (MI). All patients were hospitalized, given PFLO400mg, 2 times a day supervision, the treatment period of 6 months, before treatment according to the WHO leprosy chemotherapy program requirements of patients, after the start of treatment, monthly clinical evaluation and blood, urine and Liver function test. In addition, histological examinations and mouse footpad inoculations were performed before and at 2, 4, and 6 months of treatment to examine the proportion of viable cells and the susceptibility of Leprosy to DDS and rifampicin (RFP) before treatment. Results: Four out of ten strains of leprosy showed low primary DDS resistance, but all strains were sensitive to RFP. All patients had a good response to PFLO. At 2 months of treatment, there was a definite clinical improvement with subsided infiltration, flattened nodules, and improved nasal congestion. The average pre-treatment bacterial count was MI of 37.9% before treatment